Arkolith/Insider Trading/ELVN/Form 4

Hohl Benjamin

CHIEF FINANCIAL OFFICEREnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Jun 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$264K
Net Open-Market Flow
-$264K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 17, 2026Option exercise(M)6K$2.48$15K57K
Jun 17, 2026Sell(S)1K$42.78$59K56K
Jun 17, 2026Sell(S)3K$43.86$149K52K
Jun 17, 2026Sell(S)1K$44.75$55K51K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 17, 2026Option exercise(M)6K—$086K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001882764-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML